RxDoctor Payments Data

Arthur Marush, MD

Internal Medicine · Brooklyn, NYNPI 1003912809

Payments from drug & device makers

$2,737in general payments, 2019–2025

Across 144 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$362
  • E.r. Squibb & Sons, L.L.C.$330
  • Bayer$244
  • Pfizer$243
  • GSK$238
  • Amarin Pharma, Inc.$176
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,71399%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,737 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$461,566
Medicare patients
568
Services billed
13,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban289$330,486
JanuviaSitagliptin Phosphate165$187,780
JardianceEmpagliflozin134$164,880
OzempicSemaglutide96$119,057
XareltoRivaroxaban75$92,394
EntrestoSacubitril/Valsartan54$80,941
JanumetSitagliptin Phos/Metformin Hcl35$47,606
FarxigaDapagliflozin Propanediol34$42,315
NexletolBempedoic Acid25$20,397
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$19,957
Colesevelam Hcl53$15,222
TradjentaLinagliptin14$13,115
LinzessLinaclotide15$12,319
MyrbetriqMirabegron18$9,986
Atorvastatin Calcium753$8,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$330,486289 claims
MerckJanuvia, Janumet$362$235,387200 claims
Boehringer IngelheimJardiance, Tradjenta$92$177,995148 claims
Novo NordiskOzempic$65$119,05796 claims
Johnson & JohnsonXarelto$57$92,39475 claims
NovartisEntresto$16$80,94154 claims
AstraZenecaFarxiga, Symbicort$84$45,43148 claims
Esperion Therapeutics, Inc.Nexletol$93$20,39725 claims
GSKShingrix$238$3,08214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →